Page 9 of 11 – SEC Filing
The Reporting Persons disclaim beneficial
ownership of the securities directly held by each of the Funds, and this Amendment No. 32 shall not be deemed an admission that
the Reporting Persons are the beneficial owners of such securities for purposes of Section 13(d) or for any other purpose.
Julian C. Baker and Felix J. Baker are Directors
of the Issuer. Julian C. Baker serves as the Chair of the Nominating and Corporate Governance Committee and Felix J. Baker serves
as the Chair of the Compensation Committee and serves on the Science & Technology Committee of the Issuer’s Board.
Felix J. Baker and Julian C. Baker serve on the Issuer’s
Board as representatives of the Funds. Due to the agreements and policies of the Funds, Felix J. Baker and Julian C. Baker do not
have any right to receive any profits from any securities received as compensation for serving as Directors of the Issuer and therefore
have no pecuniary interest in the common stock, shares of restricted stock received in lieu of director retainer fees (“Restricted
Stock”) or options to purchase common stock of the Issuer (“Stock Options”) received by Felix J. Baker or Julian
C. Baker as director compensation. The Funds are entitled to the pecuniary interest in such common stock, Restricted Stock and
Stock Options as each holds an indirect pecuniary interest. Felix J. Baker and Julian C. Baker, solely as a result of their ownership
interest in the general partners of the general partners of the Funds, may be deemed to have an indirect pecuniary interest in
such common stock, Restricted Stock and Stock Options (i.e. no direct pecuniary interest).
The Adviser has voting and investment power over the common
stock, Restricted Stock and Stock Options held by Julian C. Baker and Felix J. Baker received as director compensation. The Adviser
GP, and Felix J. Baker and Julian C. Baker as principals of the Adviser GP, may be deemed to have the power to vote or direct the
vote of and the power to dispose or direct the disposition of such common stock, Restricted Stock and Stock Options held by Julian
C. Baker and Felix J. Baker received as director compensation.
(c) Except as disclosed herein or in any previous
amendments to this Schedule 13D, none of the Reporting Persons or their affiliates has effected any other transactions in securities
of the Issuer during the past 60 days.
(d) Certain securities of the Issuer are held
directly by 667, a limited partnership the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership
the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members
of Baker Biotech Capital (GP), LLC.
Certain securities of the Issuer are held
directly by Life Sciences, a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital, L.P.,
a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP), LLC. Julian C. Baker and
Felix J. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.
Certain securities of the Issuer are held
directly by 14159, a limited partnership the sole general partner of which is 14159 Capital, L.P., a limited partnership the sole
general partner of which is 14159 Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of 14159 Capital
(GP), LLC.
Certain securities of the Issuer are held
directly by FBB, a general partnership the sole members of which are Julian C. Baker and Felix J. Baker.
| Page 9 of 11 Pages |
